Pharma News, 2022

Clinical-stage biotechnology company, Abivax, has reported promising results from its phase 2a maintenance trial into rheumatoid arthritis (RA) after one year of continued daily treatment with 50m...

AbbVie and Gedeon Richter have entered an agreement for researching, developing and marketing new dopamine receptor modulators to potentially treat neuropsychiatric diseases.  ...

Pfizer has launched a phase 2/3 trial evaluating its COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir) in pediatric patients with symptomatic COVID-19 who haven’t been hospitalized. ...

Hybrid versions of the coronavirus that combine genes from the Delta and Omicron variants - dubbed "Deltacron" - have been identified in at least 17 patients in the United States and Europe, researche...

The EC approval is based on results from the Phase III EMPEROR-Preserved trial of 10mg empagliflozin versus placebo.

The US Food and Drug Administration (FDA) has granted approval to Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) plus platinum-doublet chemotherapy for adult resectable non-small cell lung cance...

Lonza completed a laboratory expansion project at its API manufacturing facility in Nansha, China.

Novavax Inc.’s COVID-19 vaccine is on its way towards authorization from the U.S. Food & Drug Administration after formally submitting a request in late January.  ...

Results showed a clinically meaningful prevention of bleeds in people with severe haemophilia A

COVID-19 can cause the brain to shrink, reduce grey matter in the regions that control emotion and memory, and damage areas that control the sense of smell, an Oxford University study has found. ...

AbbVie  announced that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech.

In 2012, Moti Shniberg sold his face recognition startup to Facebook and started looking for a new challenge.